Volume Spike Investor

Anadys Pharmaceuticals Inc. (NASDAQ: ANDS) is surging from ongoing Phase Ib clinical trial data of its ANA598, its investigational non-nucleoside polymerase inhibitor. This is also in patients infected with chronic Hepatitis C virus where all eight patients who received ANA598 demonstrated a rapid decline in viral load, and no patients demonstrated viral rebound while on study drug.

It does note that conclusions regarding longer-term safety and tolerability cannot be made until the results of future clinical trials of longer duration in more patients are known.

The move here is a sharp one and one with exponential volume possibilities.

Shares are up a whopping 70% at $3.20 and we have now seen 150,000 shares trade hands in the first 8-minutes of the trading day (including pre-market trading).  Average volume is a mere 76,000 shares.

Jon C. Ogg
January 8, 2009